Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Chronic Graft Versus Host Disease [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating KD025 for safety, tolerability, and activity in chronic graft-versus-host disease has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• KD025

Snippet

Sponsor: Kadmon, a Sanofi Company | Conditions: Graft vs Host Disease | Phase 2 | Status: COMPLETED | Results posted: 2023-06-28